SMi Source lesson Alzheimer's Disease: Treatment has the following microlearning topics
1. Learning Objectives
2. Introduction: Alzheimer's Disease
3. Development of Dementia and Disease Progression
4. Risk Factor Modification: Social, Mental, and Physical Activity
5. Risk Factor Modification: Exercise and Healthy Diet
6. Disease Modification versus Symptom Control
7. Cognitive Function Over Time with Disease Modification versus Symptom Control
8. Statistical Significance versus Clinical Significance
9. Currently Approved Agents
10. Nerve Cell Loss
11. Neurotransmitter Deficits
12. Receptor Deficits
13. Acetylcholinesterase (ChE)
14. Historical Overview of Agents
15. Cholinergic Side Effects: Common and Uncommon
16. Cholinergic Side Effects: Gradual Low-Dose
17. Anticholinergic Drugs
18. Mechanism of Action and Indication - Donepezil
19. Acetylcholinesterase Inhibitors - Donepezil
20. Mechanism of Action and Indication - Galantamine
21. Dosage and Administration - Galantamine
22. Clinical Studies - Overview
23. Clinical Studies in Patients with Probable AD
24. Mechanism of Action and Indication - Rivastigmine
25. Dosage and Administration - Rivastigmine Oral Dosage
26. Clinical Studies: Overview
27. NMDA Receptor Antagonist - Memantine
28. Mechanism of Action - NMDA Receptor Antagonist - Memantine
29. Indication, Dosage and Administration
30. Memantine Precautions
31. Memantine Clinical Studies: Overview
32. Search for Disease Modifying Therapies
33. New Alzheimer's Disease Treatment Strategies
34. Update to Theory of AD Pathophysiology and Potential Drug Failures
35. Overview of Neuropsychiatric Symptoms in AD
36. Treatment of Psychosis and Agitation
37. Clinical Antipsychotic Trials of Intervention Effectiveness - Alzheimers Disease (CATIE-AD)
38. Risks versus Benefits of Antipsychotics in AD
39. Treatment of Depression
40. Treatment of Sleep Disturbances
41. Self Check
